… A more potent platelet inhibition with ticagrelor or prasugrel … and aspirin, including patients
undergoing CABG [13, 14]. … antiplatelet treatment post PCI—either for stable or unstable CAD…

… Geography may also be a factor influencing … that the favorable effects of CABG over PCI for
complex CAD seen more … tool for graft failure, further trials (eg, the RFR-CABG [Resting Full-…

… An additional two treatments were performed in this study … fibrinogen which are both potent
angiogenic factors. Over the … , providing a superior graft for patients undergoing CABG. The …

… patients undergoing revascularization versus those treated … Follow‐up was also censored
14 days after all CABG … However, after excluding patients who underwent CABG, major …

… and the incidence of CAD in patients undergoing peripheral … who are candidates for coronary
artery bypass grafting (CABG), the … is a potent factor for adverse postoperative outcomes7 …

… coronary artery bypass grafting (CABG) in appropriate patients and … and extensive CAD in
ischaemic cardiomyopathy, CABG has long … Furthermore, the provision of high-potency statins, …

… -Eluting Stent-treated Patients with coronary artery disease) … antiplatelet potency and duration
to the individual patient. Early … Since genetic variants are just one influential factor affecting …

… Obstructive CAD was identified in 95.3% of patients, with PCI … of patients were referred to
coronary artery bypass grafting (… potent P2Y12 inhibitor usage rates in NSTE-ACS patients, by …

… in patients undergoing coronary artery bypass grafting (CABG). … and life quality in coronary
artery disease patients [1]. It is … which exhibits more potent platelet inhibition compared with …

… CABG patients to receive a RITA graft as part of a bilateral bypass procedure in which both
LITA and RITA was grafted to restore blood flow in CAD patients… are more potent than the …